[2-(4-fluoro-phenyl)-6-hydroxy-benzo[b]thiophen-3-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]methanone

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: [2-(4-fluoro-phenyl)-6-hydroxy-benzo[b]thiophen-3-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]methanone
• 英文别名: {2-(4-Fluoro-phenyl)-6-hydroxy-benzo[b]thiophen-3-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone；[2-(4-fluorophenyl)-6-hydroxy-1-benzothiophen-3-yl]-[4-(2-piperidin-1-ylethoxy)phenyl]methanone
• 化学式: C₂₈H₂₆FNO₃S
• 分子量: 475.584
• InChiKey: HKOBHPSQGCLOAD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.5
• 重原子数：
  34
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  78
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  N-羟乙基哌啶 在 三氯化铝 、 丙烷-1-硫醇 、 sodium hydride 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 2.25h， 生成 [2-(4-fluoro-phenyl)-6-hydroxy-benzo[b]thiophen-3-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]methanone
  参考文献：
  名称：

  Synergistic methodologies for the synthesis of 3-aroyl-2-arylbenzo[b]thiophene-based selective estrogen receptor modulators. Two concise syntheses of raloxifene

  摘要：

  Difunctionalized benzo[b] thiophene intermediates are prepared which allow fully independent elaboration of the 2-aryl position or the tether position of benzo[b]thiophene-based selective estrogen receptor modulators (SERMs). Two concise syntheses of the SERM raloxifene (Evista(R)) are presented. (C) 1999 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4039(99)00955-7

文献信息

• Benzothiophenes and related compounds as estrogen agonists
  申请人：Pfizer Inc.

  公开号：US06756388B1

  公开（公告）日：2004-06-29

  The invention is a compound of Formula (I): wherein R is —OH, R1 is —OH, R2 is —H, n is 2 or 3 and X is sulfur, or a pharmaceutically acceptable salt of a compound having Formula (1), or a pharmaceutical composition comprising a compound having Formula (1) or a pharmaceutically acceptable salt thereof, or methods of treating bone loss, breast cancer or prostate cancer comprising administering an effective amount of the compound having Formula (I) or a pharmaceutically acceptable salt thereof.

  这项发明是一种具有以下化学式（I）的化合物：其中R为—OH，R1为—OH，R2为—H，n为2或3，X为硫，或者具有化学式（1）的化合物的药用可接受盐，或者包括具有化学式（1）的化合物或其药用可接受盐的药物组合物，或者包括给予有效量具有化学式（I）的化合物或其药用可接受盐的方法，用于治疗骨质疏松症、乳腺癌或前列腺癌。
• [EN] BENZOTHIOPHENES AND RELATED COMPOUNDS AS ESTROGEN AGONISTS<br/>[FR] BENZOTHIOPHENES ET COMPOSES ASSOCIES AGONISTES DES OESTROGENES
  申请人：PFIZER INC.

  公开号：WO1995010513A1

  公开（公告）日：1995-04-20

  (EN) Benzothiophenes and related compounds of formula (1), wherein A, B, Z are independently -CH=, -CR4= or =N-; X is -S-, -O-, -NH-, -NR2, -CH2-CH2-, -CH2-CH2-CH2-, -CH2-O-; -OCH2-, -CH2-S-, -CO-, -SCH2-, -N=CR2- or -R2C=N-; Y is optionally substituted phenyl, alkyl, cycloalkyl, cycloalkenyl, heterocycle or bicyclic ring system; D is -CO-, -CR2R3-, -CONH-, -NHCO-, -CR2(OH)-, -CONR2, NOR1 CH-NO2 N-CN -NR2-CO-, -C-, -C-, -C-; E is a single bond, optionally substituted phenyl, heterocycle; Z1 is -(CH2)p W(CH2)q-, -O(CH2)p CR5R6- or -O(CH2)p W(CH2)q; G is -NR7R8, (a), (b), (c), a 5- or 6-membered saturated, unsaturated or partially unsaturated and optionally substituted heterocycle or a bicyclic amine containing 5 to 12 carbon atoms either bridged or fused and optionally substituted and R is halogen, -NR2R3, -NHCOR2, -NHSO2R2, -CR2R3OH, -CONR2R3, -SO2NR2R3, OH, -OR1, -O-COR1; are estrogen agonists which are useful for treating syndromes and diseases caused by estrogen deficiency.(FR) Benzothiophènes et composés associés de formule (1) agonistes des oestrogènes s'avérant utiles dans le traitement des syndromes et maladies dues aux déficiences en oestrogènes. Dans la formule (I), A, B, Z sont indépendamment -CH=, -CR4= ou =N-; X est -S-, -O-, -NH-, -NR2, -CH2-CH2-, -CH2-CH2-CH2-, -CH2-O-; -OCH2-, -CH2-S-, -CO-, -SCH2-, -N=CR2- or -R2C=N-; Y est phényle, alkyle, cycloalkyle, cycloalcényle, un hétérocycle, ou un système bicyclique éventuellement substitué; D est -CO-, -CR2R3-, -CONH-, -NHCO-, -CR2(OH)-, -CONR2, NOR1 CH-NO2 N-CN -NR2-CO-, -C-, -C-, -C-; E est une liaison simple, phényle éventuellement substitué, un hétérocycle; Z1 est -(CH2)p W(CH2)q-, -O(CH2)p CR5R6- ou -O(CH2)p W(CH2)q; G est -NR7R8, la formule (a), la formule (b), la formule (c), un hétérocycle à 5 ou 6 chaînons saturé, insaturé ou partiellement saturé et éventuellement substitué, ou une amine bicyclique à 5 à 12 atomes de carbone pontée ou à anneaux condensés et éventuellement substitué, et R est halogène, -NR2R3, -NHCOR2, -NHSO2R2, -CR2R3OH, -CONR2R3, -SO2NR2R3, OH, -OR1, -O-COR1.

  苯并噻吩及其相关化合物的公式（1），其中A，B，Z分别为-CH=，-CR4=或=N-；X为-S-，-O-，-NH-，-NR2，-CH2-CH2-，-CH2-CH2-CH2-，-CH2-O-；-OCH2-，-CH2-S-，-CO-，-SCH2-，-N=CR2-或-R2C=N-；Y为可选取代的苯基，烷基，环烷基，环烯基，杂环或双环系统；D为-CO-，-CR2R3-，-CONH-，-NHCO-，-CR2（OH）-，-CONR2，NOR1 CH-NO2 N-CN -NR2-CO-，-C-，-C-，-C-；E为单键，可选取代的苯基，杂环；Z1为-(CH2)p W(CH2)q-，-O(CH2)p CR5R6-或-O(CH2)p W(CH2)q；G为-NR7R8，（a），（b），（c），一种5或6个成员的饱和，不饱和或部分不饱和且可选取代的杂环或含5至12个碳原子的双环胺，可以是桥接或融合的，R为卤素，-NR2R3，-NHCOR2，-NHSO2R2，-CR2R3OH，-CONR2R3，-SO2NR2R3，OH，-OR1，-O-COR1；是雌激素激动剂，用于治疗由雌激素缺乏引起的综合症和疾病。
• Structure−Activity Relationships of Selective Estrogen Receptor Modulators:  Modifications to the 2-Arylbenzothiophene Core of Raloxifene
  作者：Timothy A. Grese、Stephen Cho、Don R. Finley、Alexander G. Godfrey、Charles D. Jones、Charles W. Lugar、Michael J. Martin、Ken Matsumoto、Lewis D. Pennington、Mark A. Winter、M. Dee Adrian、Harlan W. Cole、David E. Magee、D. Lynn Phillips、Ellen R. Rowley、Lorri L. Short、Andrew L. Glasebrook、Henry U. Bryant

  DOI：10.1021/jm9606352

  日期：1997.1.1

  The 8-arylbenzothiophene raloxifene, 1, is a selective estrogen receptor modulator which is currently under clinical evaluation for the prevention and treatment of postmenopausal osteoporosis. A series of raloxifene analogs which contain modifications to the 2-arylbenzothiophene core have been prepared and evaluated for the ability to bind to the estrogen receptor and inhibit MCF-7 breast cancer cell proliferation in vitro. Their ability to function as tissue-selective estrogen agonists in vivo has been assayed in a short-term, ovariectomized (OVX) rat model with end points of serum cholesterol lowering, uterine weight gain, and uterine eosinophil peroxidase activity. These studies have demonstrated that (1) the 6-hydroxy and, to a lesser extent, the 4'-hydroxy substituents of raloxifene are important for receptor binding and in vitro activity, (2) small, highly electronegative 4'-substituents such as hydroxy, fluoro, and chloro are preferred both in vitro and in vivo, (3) increased steric bulk at the 4'-position leads to increased uterine stimulation in, vivo, and (4) additional substitution of the 2-aryl moiety is tolerated while additional substitution at the 4-, 5-, or 7-position of the benzothiophene results in reduced biological activity. In addition, compounds in which the 2-aryl group is replaced by alkyl, cycloalkyl, and naphthyl substituents maintain a profile of in vitro and in vivo biological activity qualitatively similar to that of raloxifene. Several novel structural variants including 2-cyclohexyl, 2-naphthyl, and 6-carbomethoxy analogs also demonstrated efficacy in preventing bone loss in a chronic OVX rat model of postmenopausal osteopenia, at doses of 0.1-10 mg/kg.
• BENZOTHIOPHENES AND RELATED COMPOUNDS AS ESTROGEN AGONISTS
  申请人：PFIZER INC.

  公开号：EP0723537A1

  公开（公告）日：1996-07-31
• FLUORINE CONTAINING COMPOUNDS AND METHODS OF USE THEREOF
  申请人：Ritter Tobias

  公开号：US20120095217A1

  公开（公告）日：2012-04-19

  Fluorinated compounds and methods of making fluorinated compounds are described herein.